$LLY: Decision Zone — Wedge Breakout or Retest of 685

Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.

Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.

Bearish path (red): rejection at the wedge cap could send price back to the green trendline for a higher-low around ~685 before another attempt up.

News supporting the bullish path:

1- Mounjaro (tirzepatide) UK price hike: Lilly will lift UK list prices by up to ~170% from Sept 1, 2025 (e.g., highest doses from ~£122 to ~£330), with pharmacies flagging stockpiling/shortages. This supports revenue/ASP but may draw scrutiny.

2- Phase 3 ATTAIN-2 (orforglipron, oral GLP-1): trial met primary & key secondary endpoints in patients with obesity/overweight and Type-2 diabetes; company guiding to global regulatory submissions this year. Reports cite ~10.5% mean weight loss at the top dose. Sentiment tailwind for the obesity franchise.

Invalidation: weekly close below ~622.

Not financial advice :)